AR125090A1 - MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS - Google Patents
MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODSInfo
- Publication number
- AR125090A1 AR125090A1 ARP220100601A ARP220100601A AR125090A1 AR 125090 A1 AR125090 A1 AR 125090A1 AR P220100601 A ARP220100601 A AR P220100601A AR P220100601 A ARP220100601 A AR P220100601A AR 125090 A1 AR125090 A1 AR 125090A1
- Authority
- AR
- Argentina
- Prior art keywords
- activable
- masked
- methods
- related compositions
- cytokine
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee construcciones de citoquinas activables que incluyen: (a) una primera construcción monomérica que comprende una primera máscara peptídica (PM1), un tercer resto escindible (CM3), una primera proteína citoquina madura (CP1), un primer resto escindible (CM1), y un primer dominio de dimerización (DD1), en donde el CM1 está ubicado entre la CP1 y el DD1, y el CM3 está ubicado entre la PM1 y la CP1; y (b) una segunda construcción monomérica que comprende una segunda proteína citoquina madura (CP2), un segundo resto escindible (CM2), y un segundo dominio de dimerización (DD2), donde el CM2 está ubicado entre la CP2 y el DD2, donde: el DD1 y el DD2 se unen entre sí; y donde la ACC se caracteriza por una reducción en al menos una actividad de la CP1 y/o la CP2 en comparación con un nivel de control de dicha al menos una actividad de la CP1 y/o la CP2.The present invention provides activatable cytokine constructs including: (a) a first monomeric construct comprising a first peptide mask (PM1), a third cleavable residue (CM3), a first mature cytokine protein (CP1), a first cleavable residue ( CM1), and a first dimerization domain (DD1), where CM1 is located between CP1 and DD1, and CM3 is located between PM1 and CP1; and (b) a second monomeric construct comprising a second mature cytokine protein (CP2), a second cleavable residue (CM2), and a second dimerization domain (DD2), where CM2 is located between CP2 and DD2, where : DD1 and DD2 join each other; and wherein the ACC is characterized by a reduction in at least one CP1 and/or CP2 activity compared to a control level of said at least one CP1 and/or CP2 activity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163161913P | 2021-03-16 | 2021-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125090A1 true AR125090A1 (en) | 2023-06-07 |
Family
ID=86988807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100601A AR125090A1 (en) | 2021-03-16 | 2022-03-16 | MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR125090A1 (en) |
-
2022
- 2022-03-16 AR ARP220100601A patent/AR125090A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022020440A2 (en) | ACTIVATIVE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | |
BR112021023814A2 (en) | CYSTEINE PROTEASE INHIBITORS AND METHODS OF THEIR USE | |
AR125090A1 (en) | MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | |
CL2019002178A1 (en) | Low pH pharmaceutical composition comprising antibody constructs that activate t lymphocytes. | |
BR112023018735A2 (en) | MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | |
TWD222923S (en) | Shoe | |
MY150685A (en) | Molecules for blocking the infections by flaviviruses | |
DE59306474D1 (en) | AC CONTROLLER | |
Murdoch et al. | Proteolytic mechanisms in the ovulatory folliculo-luteal transformation | |
TWD223791S (en) | Shoe | |
TWD225212S (en) | Shoe | |
AR127274A1 (en) | CONSTRUCTIONS OF ACTIVABLE CYTOKINES, AND COMBINATION METHODS | |
TWD221398S (en) | Shoe | |
Yoon et al. | NPCC4: Climate change, energy, and energy insecurity in New York City | |
MX2024004300A (en) | Activatable cytokine constructs and related compositions and methods. | |
MX2024004301A (en) | Activatable cytokine constructs and combination methods. | |
CN208608971U (en) | A kind of gallium nitride microwave integrated circuit pulse modulated circuit | |
Murakami et al. | Synovial fluid matrix metalloproteinase-2 and-9 activities in dogs suffering from joint disorders | |
ITRM20010336A1 (en) | DIRECT RECOMBINANT HUMAN ANTIBODY AGAINST HEPATITIS C VIRUS NON-STRUCTURAL PROTEIN NS3 (HCV), CODING NUCLEIC ACID AND USES | |
BR112022021828A2 (en) | CYTOKINE IMMUNOTHERAPY | |
MX2022010160A (en) | Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion. | |
AR127275A1 (en) | CONSTRUCTIONS OF ACTIVABLE CYTOKINES AND RELATED COMPOSITIONS AND METHODS | |
ES2123669T3 (en) | DERIVATIVES OF THE PLASMINOGEN THAT ARE ACTIVATED WITH THROMBIN. | |
BR112021018124A2 (en) | Cell line comprising selection marker and uses thereof for protein production | |
CN210579323U (en) | Xenon lamp luminescence control circuit |